Abstract
The cause of Parkinson’s disease is unknown. The motor deficits of the illness are associated with a profound loss of dopamine containing neurones throughout the brain. However, postmortem studies suggest that alterations also occur in other neuronal systems including those utilising noradrenaline, 5HT, GABA, acetylcholine and neuropeptides. The primary role played by the deficit in brain dopamine content is emphasised by the ability of L-DOPA or dopamine agonist drugs to reverse the motor symptoms. However, for reasons which are unclear, the initial benefit of L-DOPA often wanes so that the long-term treatment of Parkinson’s disease is complicated by a loss of drug effect.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barbeau,A., Sourkes,T.L. and Murphy,G. (1962). Les catecholamines dans la maladie de Parkinson. In Monoamines et Systeme Nerveux Central. (ed.J.de Ajuriaguerra). Georg, Geneve & Masson, Paris. pp.247–262.
Bauman,R.J., Jameson,H.D., Weisberg,L.H., McKean,H.E. and Haack, D.G. (1980). Cigarette smoking and Parkinson’s disease. Neurology 30,839–843.
Birkmayer,W. and Hornykiewicz,O. (1961). Der L-Dioxyphenylalanin (= L-DOPA) — Effekt bei der Parkinson-Akinese. Wien.Klin.Wochensch., 73,787–788.
Boyce,S., Kelly,E., Reavill,C., Jenner,P. and Marsden,C.D. (1984). Repeated administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochem.Pharmac., 23,1747–1752.
Bradbury,A.J., Costall,B., Domeney,A.M., Jenner,P., Marsden,C.D. and Naylor,R.J. (1984). MPTP infusion into rat substantia nigra causes hypokinesia and bradykinesia, which are reversed by L-DOPA treatment. Presented at Dopamine 84, Southampton.
Burns,R.S., Chiueh,C.C., Markey,S.P., Ebert,M.H., Jacobowitz,D.M. and Kopin,I.J. (1983). A primate model of Parkinsonism: Selective destruction of dopaminergic neurones in the pars compacta of the substantia nigra by N-metyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc.Natl.Acad.Sci.U.S.A., 80,4546–4550.
Burns,R.S., Markey,S.P., Phillips,J.M. and Chiueh,C.C. (1984). The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can.J.Neurol.Sci.,11,Suppl. 1,166–168.
Chiba,K., Trevor,A. and Castagnoli,N.Jr. (1984). Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamineoxidase. Biochem.Biophys.Res.Comm., 120,574–578.
Chiueh,C.C., Markey,S.P., Burns,R.S., Johanessen,J.N., Pert,A. and Bopin,I.J. (1984) Neurochemical and behavioural effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur.J.Pharmac., 100,189–194.
Cotzias,G.C., Papavasiliou,P.J., van Woert,M.H. and Sakamoto,A. (1964). Melanogenesis and extrapyramidal disease. Fed.Proc., 23,713–718.
Cotzias,G.C., van Woert,M.H. and Schiffer,L.M. (1967). Aromatic amino acids and modification of Parkinsonism. New Engl.J.Med., 276, 374–379.
Davis,G.C., Williams,A.C., Markey,S.P., Ebert,M.H., Caine,E.D., Reichert,C.M. and Kopin,I.J. (1979). Chronic Parkinsonism secondary to intravenous injection of mepiridine analogues. Psychiat.Res., 1, 249–254.
Denton,T. and Howard,B.D. (1984) Inhibition of dopamine uptake by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a cause of Parkinson-ism. Biochem,Biophys.Res.Comm., 119,1186–1190,
Duvoisin,R.C., Eldridge,R., Williams,A., Nutt,J. and Calne,D. (1981). Twin study of Parkinson’s disease. Neurology 31,77–80.
Ehringer,H. and Hornykiewicz,O. (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschene und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin, Wochensch., 38,1238–1239.
Forno,L.S. (1982). Pathology of Parkinson’s Disease. In Movement Disorders. (Eds.C.D.Marsden and S.Fahn). Butterworth Scientific, London. pp.25–40,
Graham,D.G. (1979). On the origin and significance of neuromelanin. Arch.Path.Lab.Med., 103,359–362.
Hallman,H., Olson,L. and Jonsson,G. (1984). Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. Eur.J.Pharmacol., 97, 133–136.
Heikkila,R.E., Cabbat,F,S., Manzino,L. and Duvoisin,R.C. (1984). Effects of l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Neuropharmacology 3,711–713. Heikkila,R,E.,
Manzino,L., Cabbat,F.S. and Duvoisin,R.C. (1984b). Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-1,2,3,Ertetrahydropyridine by monoamineoxidase inhibitors. Nature 311,467–469.
Hornykiewicz,O. (1982). Brain neurotransmitter changes in Parkinson’s disease. In Movement Disorders. (Eds.C.D.Marsden and S.Fahn). Butterworth Scientific, London. pp,41–58.
Javitch,J,A,, Uhl,G.R. and Snyder,S.H. (1984). Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterisation and localisation of receptor binding sites in rat and human brain. Proc.Natl.Acad.Sci.U.S,A., 81,4591–4595.
Javoy-Agid,F., Taquet,H., Cesselin,F., Epelbaum,J., Grouselle,D., Mauborgne,A., Studler,J.M. and Agid,Y. (1984). Neuropeptides in Parkinson’s disease. In Catecholamines: Part C Neuropharmacology and Central Nervous Sytems — Therapeutic Aspects, Alan R.Liss,Inc. New York, pp.35–42.
Jenner,P., Sheehy,M.P. and Marsden,C.D. (1983). Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: Implications for the treatment of Parkinson’s disease. Brit.J,Clin, Pharmacol.,15,Suppl.2,2775–2895.
Jenner,P., Rupniak,N.M.J., Rose,S., Kelly,E,, Kilpatrick,G., Lees, A. and Marsden,C.D. (1984). l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in the common marmoset. Neurosci. Lett., 50,85–90.
Kula,N.S., Baldessarini,R.J., Campbell,A., Finklestein,S., Ram,V.J. and Neumeyer,J.L. (1984). Effects of N-substituted phenyltetra-hydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species. Life Sci., 34,2567–2575.
Langston,J.W., Ballard,P., Tetrud,J,W, and Irwin,I, (1983), Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219,979–980.
Langston,J.W., Langston,E.B. and Irwin,I. (1984a). MPTP-induced Parkinsonism in human and non-human primates — Clinical and experimental aspects. Acta Neurol.Scand.,70,Suppl. 100,49–54.
Langston,J.W, and Ballard,P.A.Jr. (1984b). Parkinsonism induced by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Implications for treatment and the pathogenesis of Parkinson’s disease. Canad. J.Neurol.Sci.,11,Suppl. 1,160–165.
Langston,J.W., Forno,L.S., Rebert,C.S. and Irwin,I. (1984c) Selective nigral toxicity after systemic administration of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res., 292,390–495.
Langston,J.W., Irwin,I., Langston,E.B. and Forno,L.S. (1984d) The importance of the ‘4–5’ double bond for neurotoxicity in primates of the pyridine derivative MPTP. Neurosci.Lett., 50,289–294.
Langston,J.W., Irwin,I., Langston,E.B. and Forno,L.S. (1984e). Pargyline prevents MPTP-induced Parkinsonism in primates. Science 225,1480.
Lyden,A., Bondesson,U., Larsson,B.S. and Lindquist,N.G. (1983). Melanin affinity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, an inducer of chronic Parkinsonism in humans. Acta Pharmacol.Toxicol. 53,429–432.
Markey,S.P., Johannessen,J.N., Chiueh,C.C., Burns,R.S. and Herkinham,M.A. (1984). Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 311,464–467.
Marsden,C.D., Parkes,J.D. and Quinn,N. (1982). Fluctuations of disability in Parkinson’s disease — Clinical aspects. In Movement Disorders. (Eds. C.D.Marsden and S.Fahn). Butterworth Scientific, London. pp.96–122.
Marsden,C.D. (1983). Neuromelanin and Parkinson’s disease. J.Neural. Trans.Suppl., 19,121–141.
Palacios,J.M. and Wiederhold,K.H. (1984). Acute administration of l-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing Parkinsonism in humans, stimulates (2-14C)-deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res., 301,187–191.
Parsons,B. and Rainbow,T.C. (1984). High-affinity binding sites for 3H-MPTP may correspond to monoamine oxidase. Eur.J.Pharmac., 102, 375–377.
Rinne,U.K. (1982). Brain neurotransmitter receptors in Parkinson’s disease. In Movement Disorders. (Eds.C.D.Marsden and S.Fahn). Butterworth Scientific, London. pp.59–74.
Saghal,A., Andrews,J.S., Biggins,J.A., Cand,J.M., Edwardson,J.A., Keith,A.B., Turner,J.D. and Wright,C. (1984). N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigro-striatal lesion in the rat. Neurosci.Lett., 48,179–184.
Schmidt,C.J., Matsuda,L.A. and Gibb,J.W. (1984) In vitro release for tritiated monoamines from rat CNS tissue by the neurotoxic compound l-methyl-phenyl-tetrahydropyridine. Eur.J.Pharmacol., 103,255–260.
Steranka,L.R., Polite,L.N., Perry,K.W. and Fuller,R.W. (1983). Dopamine depletion in rat brain by MPTP (l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Bes.Comm.Substances Abuse 4,315–322.
Wieczorek,C.M., Parsons,B. and Rainbow,T.C. (1984). Quantitative autoradiography of 3R-MPTO binding sites in rat brain. Fkir.J. Pharmacol., 98, 453–454.
Editor information
Editors and Affiliations
Copyright information
© 1986 The Contributors
About this chapter
Cite this chapter
Jenner, P., Marsden, C.D. (1986). Dopamine Neurone Destruction in Human and Animal Parkinsonism. In: Woodruff, G.N., Poat, J.A., Roberts, P.J. (eds) Dopaminergic Systems and their Regulation. Satellite Symposia of the IUPHAR 9th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-07431-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-349-07431-0_16
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-07433-4
Online ISBN: 978-1-349-07431-0
eBook Packages: MedicineMedicine (R0)